Close Menu

Webinar/Video Library

February 16, 2021
Sponsored by
Thermo Fisher Scientific

Differentiate DNA from RNA using NanoDrop Spectrophotometers

Partner Webinar

The similarity of absorbance spectra between DNA and RNA makes typical UV-Vis analysis less effective at distinguishing the two nucleic acids. It results in a greater risk of spending time and resources on downstream measurements only to find that the DNA sample was contaminated with RNA or vice versa. The researcher shoulders the responsibility of ensuring sample purity at the start for success down the line. 

This 13-minute video reviews how absorbance is used to analyze nucleic acid samples. It also shows how modern UV-Vis spectrophotometer software using chemometric modeling can detect DNA/RNA contamination in samples and provide corrected concentrations.

Sponsored by
Partner Webinar

Senior Research Scientist in the Regev Lab,
Broad Institute of MIT and Harvard

Application Scientist, Advanced Cell Diagnostics 

This on-demand webinar discusses a project at the Broad Institute to use spatial profiling to understand the disease progression of COVID-19. 

Sami Farhi of the Broad Institute shares details of the project, which performed transcriptomic and proteomic spatial analysis on lung parenchyma from rapid autopsies of patients succumbing to the disease. 

The team used NanoString GeoMx to perform whole-transcriptome, cancer transcriptome, and protein studies on 17 donor samples. More than 12 regions of interest were selected for each donor, guided by RNAScope against the SARS-CoV-2 S gene to identify regions of high and low viral load. 

Farhi and colleagues performed differential analyses of epithelial and non-epithelial compartments across different viral load, anatomical compartment, and inflammation status. Results matched conclusions from single-cell and bulk RNA sequencing data on the same samples. 

Dr. Farhi discusses how the study highlights the utility of RNAScope in guiding other spatial analysis methods as well as how the data set captures the intra- and inter-sample expression heterogeneity associated with COVID-19, highlighting both early response mechanisms to SARS-CoV-2 and subsequent late-stage responses to viral damage.

Key Learning Points:

  • Spatial variation of gene expression programs in COVID-19 tissues
  • Guiding Nanostring GeoMx experimental design with RNAScope measurements
Sponsored by
February 11, 2021
Sponsored by
Foundation Medicine

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

GenomeWebinar

Medical Director, Precision Medicine;
Geriatric Oncology Consortium

Chief, Precision Health and Genomics, Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute, H. Lee, Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program, Aurora Health Care

Lead Variant Scientist, Intermountain Healthcare

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.



Sponsored by
GenomeWebinar

Director of the Molecular Diagnostics Laboratory, Director of the Molecular Genetic Pathology Fellowship, Clinical Associate Professor of Pathology, University of Michigan

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

The evolution of molecular oncology presents enormous challenges for laboratories, including:

  • Selecting clinically relevant genomic regions using the most up-to-date medical evidence
  • Designing and optimizing an advanced NGS solution
  • Implementing bioinformatics technology for accurate variant calling
  • Utilizing expertise for variant annotation and interpretation

In this webinar, Dr. Noah Brown of the University of Michigan will discuss how his team worked with Sophia Genetics to develop an NGS solution to keep pace with the ever-evolving recommendations and clinical guidelines for myeloid malignancies. 

In particular, he will describe:

  • The optimization of laboratory resources and rationale for external collaboration
  • Myeloid panel design considerations
  • The process of implementing this new NGS capture-based solution
  • Analytical performance 
  • Experience with this platform in routine testing

Product Disclaimer: Sophia Genetics products are for Research Use Only and not for use in diagnostic procedures. The information included has been prepared for and is intended for viewing by a global audience. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representativesAny views expressed during this webinar by the presenter are those of the presenter only and do not represent Sophia Genetics' own views.

Sponsored by
January 26, 2021
Sponsored by
Paragon Genomics

SARS-CoV-2 Sequencing and High-Throughput Detection

Partner Webinar

In this on-demand webinar, speakers from Paragon Genomics and Children's Hospital Los Angeles discuss the newest applications and methods for identifying and investigating the SARS-CoV-2 genome.

Technical Specialist and Operations Manager Lily Liu introduces the Paragon team's latest research and product while Dr. Xiaowu Gai and Dr. Jennifer Dien Bard of Children's Hospital Los Angeles discuss how they have integrated the Paragon Genomics SARS-CoV-2 kit into their research workflow.

Sponsored by
GenomeWebinar

Director of Aquaculture Innovation,
Atlantic Aqua Farms

Lead Scientist, Variety Development and Bioinformatics,
Hopsteiner

Genomics Coordinator, The Center for Aquaculture Technologies (CAT)

Global Strategic Marketing Manager,
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species. But these services are not created equal. The diversity of species means that not all breeding programs can rely on well-defined reference genomes. For many species, customized enzymes and expertise help uncover more variations and make more informative decisions on breeding selections.

For example, genotyping by sequencing (GBS) is a useful approach for species where there is little or no previous genetic information available. The approach provides a means for SNP discovery for lesser interrogated species and unique populations where whole-genome sequencing would not be financially feasible due to complexities and larger genome sizes.

In this panel discussion, three experts will talk through applications of targeted genotyping by sequencing, specifically focusing on how customized enzymes coupled with expertise from LGC, Biosearch Technologies, improved their breeding programs.

Sponsored by
Partner Webinar

In this technical presentation, we will discuss the use of polymeric microspheres in diagnostic assays. We will provide you with a survey of the materials used in this field, examples of readers available for this growing market, case studies, and a first preview of novel products to be released in 2020.  Material considerations to be discussed include key attributes needed to select the best spheres for qualitative and quantitative assays (such as size, functional group, and color).  We will also share best practices to troubleshoot protein binding in qualitative assay development using our raw materials. This information will be of interest to individuals involved in developing and validating qualitative and quantitative assays.

Sponsored by
Partner Webinar

Having been on the market for over 25 years, lateral flow test strips are widely accepted as a format for the development of diagnostic assays. Devices range from simple test strips dipped into a sample to long format tests used with quantitative readers.

Lateral flow test strips are easy to run, often requiring no more than application of a liquid sample, but reliability of performance depends on how consistently the strips are constructed. This involves the materials, the chemistries, the overall design, and the assembly processes.

This on-demand webinar discusses some of the critical features of test strip design that affect the consistency of performance. These are related back to strategies for minimizing variation where possible and managing variation where it must be accepted.

Sponsored by
Partner Webinar

In this technical presentation, we will provide you with an introduction to AnteoBind nanocoating technology and the use of AnteoBind activated Estapor europium microspheres in lateral flow immunoassays.

We will discuss the common issues encountered in antibody conjugation, the detail of the alternative protein conjugation procedure using AnteoBind activated Estapor europium microspheres, and the effects of physical characteristics (size, dispersity, surface charge) during the steps of conjugation and storage. We will also discuss the performance of conjugates in functional assay development for several popular biomarkers.

We will share best practices to troubleshoot antibody conjugation to AnteoBind activated Estapor europium microspheres in assay development and the initial scale-up procedure. This information will be of interest to individuals involved in developing and validating lateral flow immunoassays and manufacturing process development.

Sponsored by
Partner Webinar

Multiomics experiments allow researchers to make important discoveries in ways that have never before been possible. However, integrating these data into a broader biological context can be challenging and time consuming when using standard resources.

Qiagen has introduced an innovative solution to this challenge: Qiagen Ingenuity Pathway Analysis (IPA) software integrated with Qiagen OmicSoft databases.

In this on-demand webinar, Lynne Mullen, Senior Scientist, Qiagen Digital Insights, presents a use case for Qiagen IPA and Qiagen OmicSoft in the analysis of changes in postnatal mouse heart tissues using transcriptomic, proteomic and metabolomic data.

These topics are discussed in this webinar:

• Sample to Insight workflows

• Processing and uploading of transcriptomic, proteomic and metabolomic data

• Biological analysis of these types of data

• Interpreting the results in a larger context

Sponsored by
Partner Webinar
This on-demand webinar discusses transcriptomic analyses of in vitro flavivirus- or coronavirus-infected cell lines.
Sponsored by
Partner Webinar

In this video, Dr. Benjamin W. Darbro talks about a study at the University of Iowa to find novel drug targets for metastatic pancreatic neuroendocrine tumors using Qiagen Ingenuity Pathway Analysis.

Sponsored by
Partner Webinar

IsoPlexis’ groundbreaking intracellular signaling omics application allows users to uniquely analyze signaling cascades of many phosphoproteins directly from each single cell, across thousands of single cells in parallel.

In this on-demand webinar, learn why it’s a critical tool for the characterization of cancer cell resistance pathways and the development of durable targeted therapies to overcome resistance.

Speakers will also discuss the solution’s impact on the fields of immune medicine and oncology, and highlight how it has been used in high-impact studies to predict and target therapeutic resistance in glioblastoma and other metastatic cancers. 

Sponsored by
GenomeWebinar

Director, Genome Center,
University of California at Davis

Senior Field Application Scientist,
UgenTec

Director, COVID Diagnostics Strategy and Market Development,
LGC, Biosearch Technologies

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control. These efforts are being integrated with the Healthy Davis Together initiative, which is providing free testing for everyone in the City of Davis. The goal is to provide at least weekly testing combined with more frequent strategic testing. This requires rapid data analysis software that minimizes the time needed to accurately call, certify, and return results. 

In this webinar, Prof. Richard W. Michelmore, director of the Genome Center at UC Davis, will describe how his team based its approach on workflows developed in the agricultural biotechnology sector that are capable of cost-effectively generating millions of data points per day. 

Prof. Michelmore will discuss details of the entire workflow, from sample collection through to a data management system that his team developed that uses Ugentec’s Fastfinder software. 

After Dr. Michelmore’s presentation, James Grayson of UgenTec will briefly discuss FastFinder, which allows labs and assay providers to build sample-to-result workflows. 

After this, Ross Higgins of LGC, Biosearch Technologies will briefly introduce how their instrumentation solutions support very large scale screening initiatives.

The presentations will be followed by an interactive Q&A session with attendees.

Sponsored by
December 14, 2020
Sponsored by
10x Genomics

Single-Cell Multi-omics to Profile the Immune System

GenomeWebinar

Head of Computational Biology 
Immunai

Profiling the immune system of cancer patients at the single-cell level promises to uncover signatures of response and mechanisms of drug action. While single-cell technologies have developed at a rapid pace, applying them to large numbers of clinical samples remains challenging. 

To overcome this challenge, researchers at Immunai developed an integrated platform that enables high-quality analysis of single-cell multi-omics data on hundreds of PBMC samples from cancer patients. Leveraging machine learning approaches to correct for sample heterogeneity and mitigate batch effects, this platform enables characterization of the transcriptome, cell surface proteins, and adaptive immune repertoire of large sample numbers at the single-cell level using 10x Genomics technology.  

In this webinar, Dr. Tali Raveh, Head of Computational Biology at Immunai, will discuss:

  • The power of an integrated platform to elucidate compelling insights from single-cell immune profiling and applications to cancer research
  • Efforts to define blood-derived early signatures of patient response and mechanisms of drug action using longitudinal blood samples from cancer patients treated with checkpoint inhibitors 
  • How to identify and characterize the dynamics and differential gene expression of T-cell clones expanding over time
Sponsored by

Pages

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Interested in Posting your Webinar or White Paper on GenomeWeb?

Contact us